Lupin challenge to levofloxacin patent term extension in US fails
Lupin challenged the validity of the PTE of the levofloxacin patent number 5,053,407, in order to seek the approval of its own generic levofloxacin products. Reportedly, on 10
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The patents cover oral formulations of leading injectables, like bevacizumab (Avastin), trastuzumab (Herceptin), adalimumab (Humira, etanercept (Enbrel), insulin glargine (Lantus), and many others. In addition, Access rebranded its